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Introduction: Inherited variability in host immune responses influences susceptibility and outcome of Influenza A
virus (IAV) infection, but these factors remain largely unknown. Components of the innate immune response may
be crucial in the first days of the infection. The collectins surfactant protein (SP)-A1, −A2, and -D and mannose-binding
lectin (MBL) neutralize IAV infectivity, although only SP-A2 can establish an efficient neutralization of poorly glycosylated
pandemic IAV strains.
Methods: We studied the role of polymorphic variants at the genes of MBL (MBL2), SP-A1 (SFTPA1), SP-A2 (SFTPA2), and
SP-D (SFTPD) in 93 patients with H1N1 pandemic 2009 (H1N1pdm) infection.
Results: Multivariate analysis showed that two frequent SFTPA2 missense alleles (rs1965708-C and rs1059046-A) and
the SFTPA2 haplotype 1A0 were associated with a need for mechanical ventilation, acute respiratory failure, and acute
respiratory distress syndrome. The SFTPA2 haplotype 1A1 was a protective variant. Kaplan-Meier analysis and Cox regression
also showed that diplotypes not containing the 1A1 haplotype were associated with a significantly shorter time to ICU
admission in hospitalized patients. In addition, rs1965708-C (P = 0.0007), rs1059046-A (P = 0.0007), and haplotype
1A0 (P = 0.0004) were associated, in a dose-dependent fashion, with lower PaO2/FiO2 ratio, whereas haplotype
1A1 was associated with a higher PaO2/FiO2 ratio (P = 0.001).
Conclusions: Our data suggest an effect of genetic variants of SFTPA2 on the severity of H1N1pdm infection
and could pave the way for a potential treatment with haplotype-specific (1A1) SP-A2 for future IAV pandemics.Introduction
Influenza A virus (IAV) infection is usually a mild and
self-limited condition. Likewise, infection with the H1N1
pandemic 2009 (H1N1pdm) IAV often results in an
uncomplicated flu, but, in a small subset of patients, it
may rapidly evolve to primary viral pneumonia, acute re-
spiratory failure (ARF), and acute respiratory distress* Correspondence: jrodgal@gobiernodecanarias.org
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article, unless otherwise stated.syndrome (ARDS) [1]. Inherited and acquired variability
in host immune responses may influence susceptibility
and outcome of IAV infection, although these factors
remain largely unknown [2-4].
Before exposure to H1N1pdm IAV, most individuals,
particularly those born after 1957, lack serum antibodies
capable of neutralizing the virus [1]. Adaptive immune
responses, which are needed for ultimate viral clearance,
take several days to develop. Therefore, components of
the innate immunity that are able to neutralize IAV in-
fection with minor inflammation may be crucial for host
defense in the first few days after infection. Different sol-
uble pattern-recognition molecules of the innate immunityCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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type lectins of the collectin family, the serum mannose-
binding lectin (MBL), the pulmonary surfactant proteins
(SP) –A1, –A2, and –D, and collectin 11 (CL-11, alias
collectin kidney 1, CL-K1) may neutralize IAV infectivity
in vitro [5-8]. Among these collectins, the SPs have been
shown to exert an important role against IAV infection in
animal models: mice lacking SP-A or SP-D have increased
susceptibility to IAV infection, and their role seem to de-
pend on IAV strains, particularly pandemic versus seasonal
strains [9-14]. In addition, variability at the collectin genes,
MBL2 (Ensembl: ENSG00000165471), SFTPA1 (Ensembl:
ENSG00000122852), SFTPA2 (Ensembl: ENSG00000185
303), and SFTPD (Ensembl: ENSG00000133661) have been
found to be associated with susceptibility to and/or severity
of several bacterial and viral infectious diseases [6,15].
It hence follows that these collectins are firm candi-
dates to explain, at least in part, the role of host
genetic variability in the defense against IAV infection.
The human SP-A locus consists of two similar genes,
SFTPA1 and SFTPA2, localized within a cluster (10q21-24)
that includes the SP-D gene (SFTPD) [16]. MBL2 was re-
ported not to be in physical linkage with the genes of these
SPs [17], but linkage disequilibrium of MBL2 with SFTPA1
and SFTPA2 has been shown; and LD among variants
at these genes could influence the results of genetic-
association studies [6,18,19].
In the present study, we assessed the role of variants
at the SFTPA1, SFTPA2, and SFTPD genes in H1N1pdm
IAV infection in humans. Variants at the neighbor col-







Figure 1 Selection process for patients with H1N1pdm 2009 infectionMaterials and methods
H1N1pdm-infected patients
We recruited 124 patients with H1N1pdm infection be-
tween July 2009 and November 2011. Thirty-one individ-
uals with ancestors other than Spanish were excluded. Of
93 unrelated white Spanish patients, 70 were hospitalized at
five tertiary Spanish hospitals, and 23 were attended at pri-
mary care centers (Figure 1). Data and samples from all
ambulatory patients and from 30% of hospitalized individ-
uals were retrospectively obtained; in the remaining pa-
tients, data were obtained prospectively. All patients were
treated with oseltamivir, and only one patient had been
previously vaccinated against H1N1pdm.
Diabetes, previous lung disease, solid-organ transplant-
ation, immunosuppression, body mass index (BMI) ≥30,
human immunodeficiency virus (HIV) infection, and preg-
nancy were considered risk factors. Sepsis, septic shock,
and multiorgan dysfunction syndrome (MODS) were de-
fined by using the American College of Chest Physicians/
Society of Critical Care Medicine criteria [20]. ARF and
ARDS were diagnosed according to the American Euro-
pean Consensus Conference Definition [21]. Functional pa-
rameters of gas exchange were calculated on the basis of
the ratio of oxygen arterial pressure to oxygen inspiratory
fraction (PaO2/FiO2). In hospitalized patients without arter-
ial blood gas analysis (n = 18), ARF was established when
hemoglobin oxygen saturation, breathing room air, was
lower than 90%. In patients with intensive care unit (ICU)
admission, severity of illness was evaluated with the Acute
Physiology and Chronic Health Evaluation II score, taking










. Infection by H1N1pdm was confirmed in all the 124 patients.
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the Helsinki declaration. The protocol was approved by
Clinical Research Ethics Committees (CEIC) of hospitals
involved (CEIC Hospital Universitario de Gran Canaria
Doctor Negrín, Las Palmas de Gran Canaria; CEIC
Hospital San Jorge, Huesca and CEIC Hospital Clínico
y Universitario de Valencia, Valencia). Informed consent
was obtained of all patients included.
Detection of H1N1pdm by real-time polymerase chain
reaction
Influenza A H1N1 virus in the 124 patients was de-
tected in nasopharyngeal swabs by using the Real-Time
ready Influenza A (H1N1) Detection Set (Roche Diagnos-
tics GmbH, Mannheim, Germany) according to manufac-
turer’s protocol.
General Spanish-population subjects
The general population group consisted of white unre-
lated Spanish healthy volunteers (blood and bone mar-
row donors as well as hospital staff ) from four tertiary
Spanish hospitals. The control group was analyzed for
MBL2 (n = 1,736) and SFTPA1 and SFTPA2 (n = 769)
polymorphisms in previous studies [18,19]. For the nine
SFTPD variants under study, 963 individuals from the
general population group recruited at the same hospitals
were analyzed in this study. The protocol was approved
by Clinical Research Ethics Committees (CEIC) of hospi-
tals involved (CEIC Hospital Universitario de Gran
Canaria Doctor Negrín, Las Palmas de Gran Canaria;
CEIC Hospital de la Princesa, Madrid; CEIC Hospital
San Jorge, Huesca and CEIC Hospital Clínico y Universi-
tario de Valencia, Valencia). Informed consent was ob-
tained of the general-population individuals included.
No data about whether individuals from the general
Spanish population group were or were not infected
with H1N1pdm were available. Foreigners and individ-
uals with ancestors other than Spanish were previously
excluded.
Selection of single-nucleotide polymorphisms
Deficient and low MBL serum levels are mainly due to the
presence of three common point mutations in the exon 1
of the MBL2 gene: alleles B (rs1800450), C (rs1800451),
and D (rs5030737) are termed O alleles, A being the wild-
type. Serum MBL levels are very low or absent in individ-
uals homozygous for O alleles. In addition, the presence of
the promoter allele X (rs7096206) has an important down-
regulating effect, and individuals with XA/O also have very
low MBL serum levels. O/O together with XA/O genotypes
are considered MBL-deficient genotypes, which are com-
mon in most populations.
The human SP-A locus consists of two similar genes,
SFTPA1 and SFTPA2, located on chromosome 10q22.3,within a cluster that includes the SP-D gene (SFTPD). In
addition, a certain degree of linkage disequilibrium (LD)
exists among SP genes and the MBL gene (10q21-24)
[18,19]. On the basis of the existence of several SNPs,
SP-A haplotypes are conventionally denoted as 6An for
the SFTPA1 gene (V19A, rs1059047; L50V, rs1136450;
R219W, rs4253527) and 1An for the SFTPA2 gene (T9N,
rs1059046; A91P, rs17886395; Q223K, rs1965708) [22].
These missense single-nucleotide polymorphisms (SNPs)
at SFTPA1 and SFTPA2 were analyzed in our study. The
most frequent conventional haplotypes of these genes,
except 1A and 1A5, can be unambiguously identified.
For the analysis of SFTPD, genotypic data of individ-
uals of European ancestry (CEU) from the International
HapMap Project [23] were used to select LD tagging
SNPs. Pairwise LD-tagging was achieved with Haploview
v. 4.2 [24] for SNPs with a minimum minor allele fre-
quency of 0.05 and r2 of 0.8. As result, three intronic
SNPs (rs10887199, rs7078012, and rs723192) and one
synonymous SNP (rs6413520) were selected. Three mis-
sense SNPs were also analyzed: rs3088308 (S290T),
rs2243639 (T180A), and rs721917 (M31T). Additionally,
we studied an SNP in the SFTPD promoter region
(rs1885551) that was recently reported to have a pro-
found impact on serum SP-D levels [25] and an intronic
SNP (rs17886286) associated with susceptibility to inva-
sive pneumococcal disease [26].
DNA extraction and genotyping
Genomic DNA was extracted from 400 μl of peripheral
blood by using iPrep PureLink gDNA Blood kit in the iPrep
Purification Instrument (Invitrogen by Life Technologies,
Carlsbad, CA, USA). Extracted DNA integrity was
checked by NanoDrop ND-1000 (NanoDrop Technologies,
Wilmington, DE, USA). In total, 19 polymorphisms at
MBL2, SFTPA1, SFTPA2 and SFTPD were studied.
MBL2, SFTPA1, SFTPA2, and SFTPD rs721917 SNPs
were analyzed by means of PCR-RFLP and PCR-SSP tech-
niques, as previously described [18,19]. The other eight
SNPs of SFTPD were determined by predesigned Taqman
SNP genotyping assays (Assays IDs: C__26726209_10,
C__26726205_10, C__31530298_10, C__63652102_10,
C__29213175_10, C___1362981_20, C____630297_10, and
C__12124527_20), according to the manufacturer’s proto-
col, with commercially available reagents by means of
ViiA™7 Real-time PCR System (Applied Biosystems, Foster
City, CA, USA).
Data analysis
The Hardy-Weinberg equilibrium was analyzed with
Haploview v. 4.2. Haplotypes were estimated in silico
with PHASE v. 2.1.1 under 1,000 permutations. Statis-
tical analyses were performed by using SPSS 20.0 (SPSS,
Inc., Chicago, IL, USA). The comparison of all genotype
Table 1 Demographic and clinical characteristics of
H1N1pdm-infected patients
Characteristics Subjects
Age (years) 43.5 ± 18.0a


































ARDS, acute respiratory distress syndrome; ARF, acute respiratory failure; ICU,
intensive care unit; MODS, multiorgan dysfunction syndrome; MV, mechanical
ventilation; PVP, Primary viral pneumonia.
aData are presented as mean ± SD or number of individuals (%). bTen patients
had secondary bacterial pneumonia, and seven patients had bacteremia
(four of them with secondary bacterial pneumonia).
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performed by using the χ2 test or Fisher Exact test when
needed, and odds ratios with 95% confidence intervals
were calculated. The relation between severity in hospi-
talized patients and genotypes was evaluated by binary
logistic regression models: age, gender, risk factors, and sec-
ondary infection (either bacteremia or secondary bacterial
pneumonia) were included as independent variables.
Comparison of the PaO2/FiO2 ratio according to gen-
etic variants was performed by a using linear regression
model adjusted by age, gender, risk factors, and second-
ary infection (either bacteremia or secondary bacterial
pneumonia).
To assess the need for ICU admission, a multivariate
analysis was performed, including the aforementioned
variables, by conditional logistic regression stratified by
hospital of origin.
Log-rank (LR) χ2 tests were calculated to compare
ICU admission according to the distribution of genetic
variants. Cox proportional hazard ratios adjusted for the
independent variables age, gender, risk factors, develop-
ment of secondary bacterial infection (pneumonia or
bacteremia), and hospital of origin were also performed.
Results
Demographic and clinical characteristics of patients are
shown in Table 1. The genotype distribution of SNPs did
not differ significantly under conditions of Hardy-
Weinberg equilibrium in all of the groups studied (data
not shown). Frequencies of the genetic variants under
analysis were not found to be significantly different be-
tween H1N1pdm-infected patients and the general
population (Table 2).
When severity of infection was evaluated in hospitalized
patients (n = 70) (Table 3), we observed that two missense
variants at SFTPA2 (rs1965708-C and rs1059046-A) were
significantly associated with the need for mechanical venti-
lation (MV) and with development of ARF and ARDS.
Most of these associations remained significant after multi-
variate analysis adjusted for age, gender, risk factors, and
secondary infection (either bacteremia or secondary bacter-
ial pneumonia). The alleles rs1965708-C and rs1059046-A
were overrepresented in patients requiring MV (P = 0.003;
OR, 2.43; and P = 0.016; OR, 3.71, respectively), and in
those who developed ARF (P = 0.006; OR, 4.09; and
P = 0.005; OR, 3.70, respectively) or ARDS (P = 0.006; OR,
17.68; and P = 0.016; OR, 3.71, respectively). The variant
rs1965708-C was also associated with septic shock
(P = 0.007; OR, 17.16). The SFTPA1 allele rs1136450-G
was also associated, although to a lower extent, with
the development of ARF (P = 0.038; OR, 2.64) and the
use of MV (P = 0.040; OR, 2.55); these associations
may be secondary to the existence of LD between
SFTPA1 and SFTPA2 variants (Figure 2).When haplotypes, based on combinations of missense
SNP, were analyzed (Table 4), the SFTPA2 haplotype 1A0
was found to be associated with the need for MV and with
the development of ARF and ARDS in hospitalized patients.
These differences were found to be independent of age,
Table 2 Distribution of genotype frequencies of collectin genes in general Spanish population and H1N1pdm-infected
patients
Variants Genotypes General Spanish population H1N1pdm-infected patients
MBL2a n = 1736 n = 93
rs1800451 (G57E)
rs1800450 (G54D) AA/AO/OO 1,032 (59.4)/615(35.4)/89 (5.1) 54 (58.1)/36 (38.7)/3 (3.2)
rs5030737 (R52C)
rs7096206 (Prom)
MBL deficiency AA + YAO/XAO + OO 1,475 (85.0)/261 (15,0) 77 (82.8)/16 (17.2)
SFTPA2 n = 769 n = 93
rs1965708 (Q223K) AA/CA/CC 22 (2.9)/244 (31.7)/503 (65.4) 4 (4.3)/33 (35.5)/56 (60.2)
rs17886395 (A91P) GG/GC/CC 623 (81.0)/134 (17.4)/12 (1.6) 72 (77.4)/19 (20.4)/2(2.2)
rs1059046 (T9N) CC/AC/AA 97 (12.,6)/349 (45.4)/323 (42.0) 14 (15.1)/48 (51.6)/31 (33.3)
SFTPA1 n = 769 n = 93
rs1059047 (V19A) TT/TC/CC 680 (88.4)/88 (11.4)/1 (0.1) 82 (88.2)/10 (10.8)/1 (1.1)
rs1136450 (L50V) CC/GC/GG 117 (15.2)/334 (43.4)/318 (41.4) 12 (12.9)/48 (51.6)/33 (35.5)
rs4253527 (R219W) CC/CT/TT 620 (80.6)/142 (18.5)/7 (0.9) 76 (81.7)/16 (17.2)/1 (1.1)
SFTPD n = 963 n = 93
rs3088308 (S290T) AA/AT/TT 829 (86.1)/129 (13.4)/5 (0.5) 77 (82.8)/14 (15.1)/2 (2.1)
rs2243639 (T180A) TT/TC/CC 373 (38.7)/449 (46.6)/141 (14.6) 42 (45.2)/42 (45.2)/9 (9.6)
rs10887199 (Intr) TT/TC/CC 759 (78.8)/189 (19.6)/15 (1.6) 71 (76.3)/20 (21.5)/2 (2.2)
rs17886286 (Intr) CC/CG/G 828 (86.0)/126 (13.1)/9 (0.9) 79 (85.0)/13 (14.0)/1 (1.0)
rs7078012 (Intr) CC/CT/TT 629 (65.3)/292 (30.3)/42 (4.4) 52 (55,.)/38 (40.9)/3(3.2)
rs6413520 (S45S) AA/AG/GG 824 (85.6)134 (13.9)/5 (0.5) 82 (88.2)/11 (11.8)/0 (0.0)
rs721917 (M31T) TT/TC/CC 356 (37.0)/438 (45.5)/169 (17.5) 36 (38/.7)/38 (40.9)/19 (20.4)
rs723192 (Intr) CC/CT/TT 757 (78.6)/195 (20.3)/11 (1.1) 70 (75.3)/21 (22.6)/2 (2.1)
rs1885551 (Prom) AA/AG/GG 766 (79.5)/182 (18.9)/15 (1.6) 72 (77.4)/19 (20.4)/2 (2.2)
aO/O together with XA/O genotypes are considered MBL-deficient genotypes. Intr, intronic region; Prom, promoter region. SNPs were added on the basis of
chromosome position.
Herrera-Ramos et al. Critical Care 2014, 18:R127 Page 5 of 12
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bacteremia or secondary bacterial pneumonia) in
multivariate analysis: P = 0.003 (data in Table 4), OR
3.73; P = 0.022; OR, 2.81; and P = 0.016; OR, 3.41, for
the need for MV, ARF, and ARDS comparisons, re-
spectively. By contrast, the SFTPA2 haplotype 1A1 was
found to be protective in a dominant model against the
requirement for MV and the development of ARF and
ARDS in the multivariate analysis (P = 0.015; OR, 0.16;
P = 0.005; OR, 0.21; and P = 0.021; OR, 0.12).
As an additional measurement of severity, we analyzed
the need for ICU admission in hospitalized patients. The
variants rs1965708-C and rs1059046-A were associated
with a higher rate of ICU admission, although only
rs1965708-C remained significant after conditional logis-
tic regression adjustment for the previously mentioned
variables and stratified by hospital of origin (P = 0.031;
OR, 2.43) (Table 3). The same analysis remained significant
at SFTPA2 haplotype 1A1 in a dominant model (P = 0.029;OR, 0.32) (Table 4). It is noteworthy that Kaplan-Meier
analysis and the log-rank test showed that the variants
rs1965708-C and rs1059046-A were associated with a sig-
nificantly shorter time to ICU admission in hospitalized
patients (Figure 3). The same analysis also showed that
ICU admission was less frequently required among patients
with the haplotype 1A1, and this difference was readily
detected in the first days after hospitalization. The effect of
these variants at the time of ICU admission remained sig-
nificant in Cox regression.
We finally evaluated the influence of genetic variants
of SFTPA1 and SFTPA2 on respiratory gas exchange in
52 hospitalized patients. SFTPA2 alleles (rs1965708-C
and rs1059046-A) and haplotypes (1A0) predisposing to
increased severity were found to be associated with sig-
nificantly lower PaO2/FiO2 ratios, independent of age,
gender, risk factors, secondary bacterial pneumonia, and
bacteremia (Figure 4). Interestingly, the effect of these
alleles or haplotypes was found to be dependent on the
Table 3 Severity of H1N1pdm infection in hospitalized patients regarding missense single-nucleotide polymorphisms
of SFTPA2 and SFTPA1
Statistical significance
Pa Pb Pa Pb
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Polymorphism Genotype frequencies Genotype comparisons Allele comparisons
rs1965708 (Q223K) CC CA AA CC vs CA + AA C vs A
ARF 48 33 (0.69) 15 (0.31) 0 (0.00) 0.027 0.018 0.006 0.006
No ARF 22 9 (0.41) 10 (0.46) 3 (0.14) 3.18 (1.12-9.01) 5.40 (1.34-21.71) 3.09 (1.35-7.04) 4.09 (1.5-11.13)
ARDS 16 14 (0.88) 2 (0.13) 0 (0.00) 0.018c 0.017 0.014 0.006
No ARDS 54 28 (0.52) 23 (0.43) 3 (0.06) 6.45 (1.35-31.25) 7.81 (1.45-42.05) 5.51 (1.24-24.51) 17.68 (2.25-138.57)
Shock 16 14 (0.88) 2 (0.13) 0 (0.00) 0.018c 0.018 0.014 0.007
No shock 54 28 (0.52) 23 (0.43) 3 (0.06) 6.45 (1.35-31.25) 7.64 (1.41-41.44) 5.51 (1.24-24.51) 17.16 (2.17-135.70)
MV 24 20 (0.83) 4 (0.17) 0 (0.00) 0.004 0.007 0.004 0.003
No MV 46 22 (0.48) 21 (0.46) 3 (0.07) 5.46 (1.61-18.47) 18.60 (2.23-155.24) 4.57 (1.49-13.97) 12.78 (2.39-68.42)
ICUe 30 23 (0.77) 7 (0.23) 0 (0.00) 0.014 0.019 0.010 0.031
No ICUe 40 19 (0.48) 18 (0.45) 3 (0.08) 3.64 (1.27-10.42) 2.98 (1.19-7.46) 3.25 (1.29-8.16) 2.43 (1.09-5.45)
rs1059046 (T9N) AA AC CC AA vs AC + CC A vs C
ARF 48 20 (0.42) 24 (0.50) 4 (0.08) 0.020 0.011 0.017 0.005
No ARF 22 3 (0.14) 14 (0.64) 5 (0.23) 4.52 (1.18-17.24) 8.02 (1.61-39.98) 2.40 (1.16-4.98) 3.70 (1.48-9.30)
ARDS 16 9 (0.56) 6 (0.38) 1 (0.06) 0.023 0.014 - 0.016
No ARDS 54 14 (0.26) 32 (0.59) 8 (0.15) 3.68 (1.15-11.77) 5.47 (1.42-21.13) - 3.71 (1.28-10.72)
MV 24 11 (0.46) 12 (0.50) 1 (0.04) - 0.039 - 0.016
No MV 46 12 (0.26) 26 (0.57) 8 (0.17) - 3.59 (1.07-12.10) - 2.97 (1.22-7.19)
ICUe 30 14 (0.47) 14 (0.47) 2 (0.07) 0.033 - 0.036 -
No ICUe 40 9 (0.23) 24 (0.60) 7 (0.18) 3.01 (1.07-8.48) - 2.11 (1.04-4.27) -
rs1136450 (L50V) GG GC CC CC vs GC + GG G vs C
ARF 48 21 (0.44) 25 (0.52) 2 (0.04) 0.028c 0.019 0.024 0.038
No ARF 22 5 (0.23) 12 (0.55) 5 (0.23) 6,77 (1.20-38.22) 19.80 (1.64-238.70) 2.31 (1.11-4.81) 2.60 (1.05-6.42)
MV 24 11 (0.46) 13 (0.54) 0 (0.00) 0.044 - - 0.040
No MV 46 15 (0.33) 24 (0.52) 7 (0.15) 1.62 (1.33-1.96) - - 2.55 (1.04-6.22)
aP value for the bivariate comparison calculated with the χ2 test. bP value for the multivariate analysis calculated with binary logistic regression, including the
variables age, gender, risk factors, secondary bacterial pneumonia, and bacteremia. cap value by Fisher Exact test. dip value for the multivariate analysis calculated
with binary logistic regression, including the variables age, gender, risk factors, and secondary bacterial pneumonia (bacteremia variable was excluded because it
shows a co-lineal relation with the variable mechanical ventilation). ePatients who required (ICU) or did not require (No ICU) ICU admission, P value for the multivariate
analysis calculated with conditional logistic regression stratified by hospital of origin, including the co variables age, gender, risk factors, secondary bacterial pneumonia,
and bacteremia. Only those comparisons with P< 0.05 and significant odds ratios were included. OR (95% CI), Odds ratio (95% confidence interval); ARF, acute respiratory
failure; ARDS, acute respiratory distress syndrome; MV, mechanical ventilation; ICU, intensive care unit.
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P = 0.0007, P = 0.0007 and P = 0.0004 for rs1965708-C,
rs1059046-A, and 1A0 respectively. The 1A1 haplotype,
which was associated with lesser severity, was also asso-
ciated with higher PaO2/FiO2 ratios (P = 0.0007), and
this effect was also found to be dose-dependent in a lin-
ear regression model adjusted for the same independent
variables (P = 0.0014) (Figure 4).
Discussion
Glycosylation of hemagglutinins may be an important
mechanism by which IAV can evade recognition byantibodies in an immune population. By contrast, glycosyla-
tion of hemagglutinins is important in determining sensitiv-
ity of IAV to recognition by collectins [7,27]. SP-D and
MBL bind to mannose-rich glycans on the hemagglutinins
and neuraminidase glycoproteins of IAV, agglutinating viral
particles and inhibiting infectivity and neuraminidase activ-
ity [7]. Among the known human collectins, SP-D has the
strongest in vitro capability of aggregating and neutralizing
activity of IAV [7,12,27]. Hemagglutinins from all available
strains of pandemic influenza viruses show significantly
lower glycosylation sites compared with seasonal strains;
and pandemic viruses, particularly H1N1pdm, were found
SFTPA2 SFTPA1 SFTPD
Figure 2 Linkage disequilibrium (D’) among genetic polymorphisms of surfactant proteins in general Spanish population (N = 687). LD
plots for pair wise Dʹ between markers and Dʹ values are indicated in percentages within squares in the LD plot. Strong LD is indicated by dark
gray/red, whereas light gray/pink and white indicate uninformative and low confidence values, respectively.
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http://ccforum.com/content/18/3/R127to be resistant to the antiviral activities of SP-D, MBL, and
the pentraxin PTX3 [7,13,27]. We have not observed any
association with severity when deficient-, low-, or
high-MBL producer genotypes and SFTPD SNPs or
haplotypes were compared (data not shown). Interestingly,
SP-A binding to hemagglutinins and SP-A-dependent IAV
neutralization in vitro are not influenced by the extent of
hemagglutinins glycosylation. SP-A is slightly more effective
than SP-D at neutralizing nonglycosylated IAV strains, and
it neutralizes IAV strains resistant to SP-D [12].
Accordingly, our results point toward a role of SFTPA2
SNPs and haplotypes, particularly haplotypes 1A0 and 1A1,
in the severity of H1N1pdm infection. The rationale for
such an association seems to be the involvement of SFTPA2
variants in gas-exchange parameters, which, in the case
of pulmonary IAV infection, is largely dependent on
IAV-induced lung inflammation.
Besides its role in IAV neutralization, the hydrophilic
SP-A and -D have been shown to have an antiinflamma-
tory function. Binding of the carbohydrate-binding rec-
ognition domains (CRDs) to signal-inhibitory regulatory
protein α (SIRPα) on alveolar macrophages suppresses
NF-κB activation and inflammation, allowing the healthy
lung to remain in a quiescent state. SP-A and SP-D can
also inhibit inflammation, through the CRD, blocking
Toll-like receptors 2 and 4. Pulmonary clearance of IAVwas reduced, and pulmonary inflammation and severity
were increased in Sftpa−/−mice compared with wild-
type mice [10,11]. SP-A was also found to disturb the
host inflammatory response to IAV infection in mouse
models without directly influencing viral growth and
spread, and even without demonstrable viral binding, at
least when the virus was resistant to neutralization by
SP-D [9]. Insufficient amounts of surfactant, particularly
SP-A, have been observed in prematurely born infants
with respiratory distress syndrome (pRDS). The haplo-
type 1A0 or SFTPA1-SFTPA2 haplotypes containing 1A0
have been repeatedly associated with the development
of pRDS, whereas SP haplotypes containing 1A1 were
found to be protective against that condition [5,15].
These findings parallel those observed in our study, sug-
gesting that 1A0 and 1A1 might influence the inflamma-
tory response and the severity of H1N1pdm infection
without binding to IAV.
Human SP-A1 and –A2 have similar in vitro
hemagglutination-inhibition activity of IAV strains exhibit-
ing non- or poorly glycosylated hemagglutinins heads [14].
However, in all functional assays, SP-A2 is more active than
SP-A1 [5,15]. So it is not surprising that among all the
genetic variants of collectins analyzed in our study, only a
few alleles and haplotypes of SFTPA2 were associated with
H1N1pdm severity in hospitalized patients. Furthermore,
Table 4 Severity of H1N1pdm infection in hospitalized patients regarding haplotypes of SFTPA2
Statistical significance
Pa Pb Pa Pb
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Haplotype Diplotype frequencies Diplotype comparisons Haplotype comparisons
1A0 (AGC) 1A0/1A0 1A0/rest Rest/rest 1A0/1A0 vs 1A0/rest + rest/rest 1A0 vs rest
ARF 48 16 (0.33) 27 (0.56) 5 (0.10) 0.031 0.045 0.023 0.022
No ARF 22 2 (0.09) 14 (0.64) 6 (0.27) 5.00 (1.04-24.10) 6.38 (1.04-38.97) 2.30 (1.11-4.76) 2.81 (1.16-6.77)
ARDS 16 8 (0.50) 7 (0.44) 1 (0.06) 0.020c 0.013 0.029 0.016
No ARDS 54 10 (0.19) 34 (0.63) 10 (0.19) 4,40.(1.33-14.56) 5.44 (1.43-20.77) 2.56 (1.08-6.02) 3.41 (1.26-9.22)
MV 24 11 (0.46) 12 (0.50) 1 (0.04) 0.005 0.004 0.007 0.003
No MV 46 7 (0.15) 29 (0.63) 10 (0.22) 4.72 (1.51-14.69) 7.03 (1.83-26.95) 2.78 (1.31-5.83) 3.73 (1.55-9.00)
1A1 (CGA) 1A/1A1 1A1/rest rest/rest 1A1/1A1 + 1A1/rest vs rest/rest 1A1 vs rest
ARF 48 0 (0.00) 11 (0.23) 37 (0.77) 0.009 0.0017 0.004 0.005
No ARF 22 2 (0.09) 10 (0.46) 10 (0.46) 0.25 (0.08-0.73) 0.08 (0.02-0.39) 0.23 (0.11-0.68) 0.21 (0.07-0.62)
ARDS 16 0 (0.00) 2 (0.12) 14 (0.88) - 0.040 - 0.021
No ARDS 54 2 (0.04) 19 (0.35) 33 (0.61) - 0.16 (0.03- 0.92) - 0.12 (0.02-0.73)
MV 24 0 (0.00) 4 (0.17) 20 (0.83) 0.037 0.019 0.034 0.015
No MV 46 2 (0.04) 17 (0.37) 27 (0.59) 0.28 (0.08-0.97) 0.08 (0.01-0.66) 0.31 (0.1-0.96) 0.16 (0.04-0.70)
ICUe 30 0 (0.00) 4 (0.13) 26 (0.87) 0.003 0.015 0.003 0.029
No ICUe 40 2 (0.05) 17 (0.43) 21 (0.53) 0.17 (0.05-0.58) 0.25 (0.08-0.76) 0.20 (0.07-0.62) 0.32 (0.11-0.89)
Only those comparisons with P < 0.05 and significant odds ratio were included. OR (95% CI), odds ratio (95% confidence interval); ARF, acute respiratory failure;
ARDS, acute respiratory distress syndrome; MV, mechanical ventilation; ICU, intensive care unit.
aP value for the bivariate comparison calculated with the χ2 test. b + - + value for the multivariate analysis calculated with binary logistic regression, including the variables
age, gender, risk factors, secondary bacterial pneumonia, and bacteremia. c P value by Fisher Exact test. dP value for the multivariate analysis calculated with binary logistic
regression, including the variables age, gender, risk factors, and secondary bacterial pneumonia (bacteremia variable was excluded because it shows a co-lineal relation with
the variable mechanical ventilation). ePatients who required (ICU) or did not require (No ICU) ICU admission, P value for the multivariate analysis calculated with conditional
logistic regression stratified by hospital of origin, including the covariables age, gender, risk factors, secondary bacterial pneumonia, and bacteremia. Conventional haplotypes
at SFTPA2 were identified on the basis of combinations of the polymorphism rs1059046 (T9N), rs17886395 (A91P), and rs1965708 (Q223K). “Rest” refers to
the other haplotypes for each comparison.
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http://ccforum.com/content/18/3/R127the effect of the SFTPA2 variants on the need for ICU ad-
mission was detected in the first few days of hospitalization,
as would be expected for components of the innate im-
munity involved in inflammation and defense against IAV
infection.
The significance of the functional differences between
variants at SFTPA1 and SFTPA2 is poorly understood
[5,15]. The variant rs1965708 produces an amino-acid
change at residue 223 (Q223K), located in the CRD of
SP-A2, and might directly influence the binding proper-
ties to either IAV or the antiinflammatory receptor
SIRPα. Residue 9 (rs1059046, T9N) is located in the sig-
nal peptide, and it is unknown whether this variant may
affect the protein. It is, however, worth noting that
haplotypes 1A0 and 1A1 differ precisely at residues 9 and
223. A role of SNPs at regulatory regions in haplotypes
1A0 and 1A1 in translation and/or RNA stability of
SFTPA2 cannot be ruled out [5,15]. Interestingly, SP-A2
1A1 variants were shown to have a lower activity for
enhancement of TNF-α in macrophage-derived THP-1
cells than other variants, such as 1A and 1A0, particularlyafter oxidative stress [28,29]. These data suggest that the
protective effect of the SP-A2 1A1 variant in the severity of
H1N1pdm infection could be due to its lower proinflam-
matory activity.
Irrespective of the causal SNP(s), our data suggest that
the haplotype 1A0 of SFTPA2 is associated with a higher
severity after H1N1pdm infection, whereas the SFTPA2
haplotype 1A1 was associated with a dominant protective
effect against severe forms of H1N1pdm infection.
We acknowledge several limitations of our study. First,
the overrepresentation of hospitalized patients, could
bias us to analyze susceptibility to H1N1pdm infection.
In addition, our control group could be considered a
representative sample from the Spanish population ra-
ther than a representation of non-H1N1pdm-infected
individuals.
Second, our study is underpowered to detect the role
of some variants on severity of H1N1pdm infection.
Nevertheless, considering odds ratios and a significance
level of 5%, the power of the associations of rs1965708-
C with the development of ARDS and septic shock was
Figure 3 Kaplan-Meier estimation of days until ICU admission in hospitalized H1N1pdm-infected patients according to SFTPA2
variants. Only those comparisons with P < 0.05 were included. Solid curves represent the most frequent variant under study, and the dotted
curves, the rest of variants. Significance levels calculated by means of log-rank test and Cox regression stratified by hospital of origin and adjusted
for the variables age, gender, risk factors, secondary bacterial pneumonia and bacteremia are shown at the bottom of the figure. HR (95% CI),
hazard ratio (95% confidence interval).
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http://ccforum.com/content/18/3/R12784%, and more than 88% for the need for MV. In the
haplotype analysis, statistical power was 88.56% for the
effect of the haplotype 1A1 on ICU admission (90.62%
for the effect in a dominant model). No correction for
multiple comparisons was performed in these compari-
sons, but, as expected by in vivo and in vitro studiesamong the human collectins, only SP-A would be ex-
pected to influence H1N1pdm infectivity, and significant
associations were repeatedly observed with several clin-
ical phenotypes. Furthermore, the observed associations
were found to be independent of age, gender, risk factors
predisposing to severe H1N1 infection, and development
Figure 4 Ratio of oxygen arterial pressure to oxygen inspiratory fraction (PaO2/FiO2) with regard to SFTPA2 genetic variants. PaO2/FiO2
with regard to alleles and haplotypes (a) as well as genotypes and diplotypes (b) of SFTPA2 in hospitalized patients with H1N1 pandemic 2009
influenza A virus infection. Each bar represents the mean ± SD. P values were calculated with a regression lineal model, including the variables
age, gender, risk factors, secondary bacterial pneumonia, and bacteremia.
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Variants of SFTPA2 were clearly associated with func-
tional parameters of gas exchange, underscoring their
role in the severity of H1N1pdm-induced lung injury.
Third, criteria for ICU admission may vary between
different centers. To avoid these differences, multivariate
and Cox regression analysis to evaluate the need for ICU
admission were stratified by hospital of origin.Conclusion
Our study suggests that variants at SFTPA2 influence
the severity of H1N1pdm infection in hospitalized pa-
tients. The potential of collectins as therapeutic agents
for the treatment of IAV-mediated disease is now being
explored [7,30]. In Sftpa−/−and Sftpd−/−mice, intratra-
cheally administered SP-A or SP-D can restore microbial
clearance and inflammation [5], and exogenous surfac-
tant preparations containing the hydrophobic SP-B and
-C are widely used for replacement therapies in pRDS.
The data from our study, together with a better know-
ledge of the functional significance of the geneticvariability at SFTPA2 on IAV-associated disease, could
pave the way for a potential treatment with haplotype-
specific (1A1) SP-A2 for patients with the most severe
forms of the disease in future IAV pandemics.
Key messages
 Genetic variation in the SFTPA2 gene influences the
outcome of patients infected with the 2009
pandemic H1N1 influenza A virus.
 Data from our study may help to identify patients at
higher risk of severe pandemic (nonglycosylated)
IAV infection, who may eventually benefit from
more-personalized and targeted therapies.
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